Protocadherin FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation—a cohort study with clinico-pathological correlations
Clinical Kidney Journal · 02.03.2026 · 19 (3)
DOI: 10.1093/ckj/sfag005 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Kidney Journal, online erschienen am 10.01.2026. Verfasst von Maja C Nackenhorst und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Medical University of Vienna, Vienna, Austria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The identification of causative antigens for membranous nephropathy (MN) has revolutionized the comprehension of the pathophysiology of this autoimmune disease and its management. Recently, some studies described protocadherin FAT1 (FAT1) as a causal antigen in the context of hematopoietic stem cell transplantation (HSCT). The aim of this study was to investigate the large Viennese kidney biopsy collection at the Department of Pathology of the Medical University of Vienna and explore MN cases after HSCT for the causative antigen.
Methods
Fifteen patients were identified with MN in diagnostic renal biopsies for proteinuria/nephrotic syndrome after HSCT between 2001 and 2024. Cases were reviewed and tested for the expression of FAT1 by immunofluorescence specifically.
Results
Immunofluorescence showed that 12 out of 15 patients with MN had FAT1 expression, appearing 2.3 years after HSCT. In three patients without FAT1 expression, MN appeared 3.8 years after HSCT, with one testing positive for phospholipase A2 receptor (PLA2R) and two with unknown antigens. Serum creatinine for FAT1+ MN was 1.2 mg/dl, while FAT1− MN was 1.3 mg/dl. Proteinuria was 8 g/g compared to 10.4 g/g, respectively. IgG4 positivity was seen in 30% of FAT1+ MN cases. Over a follow up of 5.2 years, of the seven FAT1+ MN patients treated with rituximab, four achieved complete remission, two partial remission, and one was non-responsive.
Conclusion
This hitherto largest single-center-cohort solidifies FAT1 as a causative antigen for MN in the setting of HSCT. However, not all post-HSCT-MN are related to FAT1.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Medical University of Vienna, Vienna, Austria.
- Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Nephrology Department, Bolzano Hospital, Italy.
- Department of Nephrology, Hypertension, Transplant Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz Elisabethinen, Linz, Austria.
ORCID-Profile: Maja C Nackenhorst, Nicolas Kozakowski
Zitieren
APA
Nackenhorst, M. C., Milovanovic, D., Schmidt, A., Mongera, N., Köller, M., Passler, W., Cejka, D., & Kozakowski, N. (2026). Protocadherin FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation—a cohort study with clinico-pathological correlations. Clinical Kidney Journal, 19(3). https://doi.org/10.1093/ckj/sfag005
Vancouver
Nackenhorst MC, Milovanovic D, Schmidt A, Mongera N, Köller M, Passler W, et al. Protocadherin FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation—a cohort study with clinico-pathological correlations. Clinical Kidney Journal. 2026;19(3). doi:10.1093/ckj/sfag005
BibTeX
@article{Nackenhorst2026,
author = {Nackenhorst, Maja C and Milovanovic, Daniela and Schmidt, Alice and Mongera, Nicola and Köller, Maximilian and Passler, Werner and Cejka, Daniel and Kozakowski, Nicolas},
title = {Protocadherin FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation—a cohort study with clinico-pathological correlations},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {3},
doi = {10.1093/ckj/sfag005}
}
EUVIMED